ASBP.US Aspire BioPharma, Inc.

Consumer Cyclical Pharmaceuticals USA Stocks
8.41 USD
Close of Nov 14, 2026
3.31 205.20
Market cap
USD 11.8M
P/E
-
P/B
1.00x
ROE
-76.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ASBP.US undervalued?

Graham number

The Graham number of Aspire BioPharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aspire BioPharma, Inc. fundamental analysis

No fundamental analysis for Aspire BioPharma, Inc. yet.

Aspire BioPharma, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aspire BioPharma, Inc.

Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems. The company develops a nano-technology-based sublingual drug delivery system designed to enhance the pharmacokinetic performance of active pharmaceutical ingredients, supplements, and nutraceuticals to increase bioavailability, improve speed of onset, and reduce side effects. Its lead prescription product candidate, Sublingual High Dose Aspi…

Full company profile